Is Senti Biosciences, Inc. (SNTI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 132.6% / 30% | 190.3% / 30% | 7.1% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 132.6% / 33% | 190.3% / 33% | 7.1% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 34.4% / 33% | 49.3% / 33% | 1.8% / 33% | N/A | ✗ NOT HALAL |
| S&P | 132.6% / 33% | 190.3% / 33% | 7.1% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 34.4% / 33% | 49.3% / 33% | 1.8% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -37095.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -218.1% | |
| Return on Assets (ROA) | -48.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$41M |
| Free Cash Flow | -$41M |
| Total Debt | $34M |
| Debt-to-Equity | 516.9 |
| Current Ratio | 1.7 |
| Total Assets | $98M |
Price & Trading
| Last Close | $0.88 |
| 50-Day MA | $0.95 |
| 200-Day MA | $1.54 |
| Avg Volume | 228K |
|
52-Week Range
$0.79
| |
About Senti Biosciences, Inc. (SNTI)
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Senti Biosciences, Inc. (SNTI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Senti Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Senti Biosciences, Inc.'s debt ratio?
Senti Biosciences, Inc.'s debt ratio is 132.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 34.4%.
What are Senti Biosciences, Inc.'s key financial metrics?
Senti Biosciences, Inc. has a market capitalization of $25M. Return on equity stands at -218.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.